...
首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions.
【24h】

Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions.

机译:两性调节蛋白和表皮生长因子受体在人乳腺癌中的表达:自体和间质-上皮相互作用的分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Amphiregulin (AR) and its receptor, epidermal growth factor receptor (EGFR), were evaluated by dual immunostaining in a series of 84 invasive ductal breast carcinoma specimens, 33 of which were from locally advanced inflammatory (T4d) cancer. Co-expression of AR and EGFR was always found in non-malignant breast tissues adjacent to tumours (24/24). Alternatively, expression of AR and EGFR was found in invasive epithelial tumour cells in 50% and 17.8% of specimens, respectively. In tumour stroma, 59.5% and 30.9% of specimens, respectively, were positively stained. By univariate analysis, AR and EGFR expression in invasive carcinomas was correlated with large tumour size, inflammatory carcinoma, node involvement, Bloom-Richardson (SBR) grade III, and absence of oestrogen receptor. EGFR expression in stromal cells was correlated with non-inflammatory carcinoma. A putative autocrine loop with AR and EGFR expression in invasive carcinoma was detected in 14.3% of cases. Stromal expression of AR and EGFR expression in invasive tumour cells was detected in 11.9% of cases and related to poor prognostic parameters. By multivariate analysis, AR expression in invasive tumour was strongly related to inflammatory carcinoma (p=0.005) and marginally related to SBR grade III (p=0.07). EGFR expression in invasive tumour and stromal cells was correlated with absence of oestrogen receptor and non-inflammatory carcinoma (p=0.002 and p=0.015, respectively). Copyright 2001 John Wiley & Sons, Ltd.
机译:通过双重免疫染色,在一系列84例浸润性导管癌样本中评估了双调蛋白(AR)及其受体,表皮生长因子受体(EGFR),其中33例来自局部晚期炎症(T4d)癌。总是在与肿瘤相邻的非恶性乳房组织中发现AR和EGFR的共表达(24/24)。或者,在侵袭性上皮肿瘤细胞中分别在50%和17.8%的标本中发现了AR和EGFR的表达。在肿瘤基质中,分别有59.5%和30.9%的样本被阳性染色。通过单因素分析,浸润性癌中AR和EGFR的表达与大肿瘤,炎性癌,淋巴结受累,Bloom-Richardson(SBR)III级和缺乏雌激素受体相关。基质细胞中的EGFR表达与非炎性癌相关。在浸润性癌中检测到具有AR和EGFR表达的推定自分泌环,占14.3%。在11.9%的病例中检测到AR和EGFR在感染性肿瘤细胞中的基质表达,与不良的预后相关。通过多变量分析,浸润性肿瘤中的AR表达与炎性癌密切相关(p = 0.005),与SBR III级密切相关(p = 0.07)。 EGFR在浸润性肿瘤和基质细胞中的表达与雌激素受体和非炎性癌的缺乏相关(分别为p = 0.002和p​​ = 0.015)。版权所有2001 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号